461 related articles for article (PubMed ID: 23359095)
1. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
2. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
3. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
[TBL] [Abstract][Full Text] [Related]
4. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
5. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
6. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
7. The roles of orexins in sleep/wake regulation.
Mieda M
Neurosci Res; 2017 May; 118():56-65. PubMed ID: 28526554
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
[TBL] [Abstract][Full Text] [Related]
9. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
10. Orexin receptors: pharmacology and therapeutic opportunities.
Scammell TE; Winrow CJ
Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
[TBL] [Abstract][Full Text] [Related]
11. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders.
Tsuneki H; Wada T; Sasaoka T
Pharmacol Ther; 2018 Jun; 186():25-44. PubMed ID: 29289556
[TBL] [Abstract][Full Text] [Related]
12. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
Gotter AL; Webber AL; Coleman PJ; Renger JJ; Winrow CJ
Pharmacol Rev; 2012 Jul; 64(3):389-420. PubMed ID: 22759794
[TBL] [Abstract][Full Text] [Related]
13. Hypocretin and its emerging role as a target for treatment of sleep disorders.
Cao M; Guilleminault C
Curr Neurol Neurosci Rep; 2011 Apr; 11(2):227-34. PubMed ID: 21170610
[TBL] [Abstract][Full Text] [Related]
14. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders.
Nishino S
Expert Opin Investig Drugs; 2007 Nov; 16(11):1785-97. PubMed ID: 17970638
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant: something new for sleep?
Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
[TBL] [Abstract][Full Text] [Related]
16. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
Yin J; Mobarec JC; Kolb P; Rosenbaum DM
Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
[TBL] [Abstract][Full Text] [Related]
18. Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties.
Coleman PJ; Schreier JD; Cox CD; Breslin MJ; Whitman DB; Bogusky MJ; McGaughey GB; Bednar RA; Lemaire W; Doran SM; Fox SV; Garson SL; Gotter AL; Harrell CM; Reiss DR; Cabalu TD; Cui D; Prueksaritanont T; Stevens J; Tannenbaum PL; Ball RG; Stellabott J; Young SD; Hartman GD; Winrow CJ; Renger JJ
ChemMedChem; 2012 Mar; 7(3):415-24, 337. PubMed ID: 22307992
[TBL] [Abstract][Full Text] [Related]
19. The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress.
Chow M; Cao M
Nat Sci Sleep; 2016; 8():81-6. PubMed ID: 27051324
[TBL] [Abstract][Full Text] [Related]
20. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness.
Ohno K; Sakurai T
Front Neuroendocrinol; 2008 Jan; 29(1):70-87. PubMed ID: 17910982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]